hrp0084p2-188 | Adrenals | ESPE2015

Phosphoglucomutase-1 Deficiency Presented as Adrenal Insufficiency

Loewenthal Neta , Parvari Ruti , Haim Alon , Tavashi Judy , Hetshkovits Eli

Background: The congenital disorders of glycosylation (CDG) are a group of genetic diseases owed to defects in the biosynthesis of glycoproteins and other glycoconjugates. Phosphoglucomutase type 1(PGM1) deficiency is classified among the CDG. Varied range of clinical manifestations recently described includes hepatopathy, bifid uvula, malignant hyperthermia, hypogonadotropic hypogonadism, growth retardation, hypoglycaemia, myopathy, dilated cardiomyopathy, and cardiac arrest,...

hrp0089lb-p10 | Late Breaking P1 | ESPE2018

The Influence of Oil-Soluble Iodinated Contrast Medium (Lipiodol) on Child’s Thyroid Function in Mice

Hongyo Tadashi , Namise Masahiro , Sawai Yukimitsu , Ishibashi Io , Kuchino Hirofumi , Seki Itsuki , Hirose Shota , Yamamura Kentaro , Ueda Yasuyuki

Introduction: Hysterosalpingography using oil-soluble iodinated contrast medium (ethiodized oil; Lipiodol) is a common examination for patients with infertility. Lipiodol remains in the body long after the examination, and there are some reports suggesting that Lipiodol induces thyroid dysfunction not only to the mother but also the fetus and the newborn. However, since there are no known mouse models of Lipiodol-induced thyroid dysfunction, we examined the influence of Lipiod...

hrp0092p1-298 | Adrenals and HPA Axis (2) | ESPE2019

First Morning Pregnanetriol and 17-Hydroxyprogesterone Correlated Significantly Each Other with in 21-Hydroxylase Deficiency

Itonaga Tomoyo , Izawa Masako , Hamajima Takashi , Hasegawa Yukihiro

Background: Biochemically monitoring 21-hydroxylase deficiency (21OHD) treatment is challenging. Serum/blood 17-hydroxyprogesterone (17OHP) measurements, especially in the early morning before medication, are traditionally used for this purpose. Urinary pregnanetriol (PT), a urinary metabolite of 17OHP, may also be used. Based on auxological data, we previously reported that the first morning PT value in the range of 2.2–3.3 mg/gCr is optimal for monitori...

hrp0092p1-170 | Bone, Growth Plate and Mineral Metabolism (1) | ESPE2019

Efficacy and Safety of Denosumab Treatment in a Boy with Cherubism

Kawamura Haruka , Watanabe Satoshi , I Takashi , Asahina Izumi , Moriuchi Hiroyuki , Dateki Sumito

Introduction: Denosumab is an inhibitor of receptor activator of nuclear factor kappa-B ligand that strongly suppresses differentiation and function of osteoclasts. Cherubism is a rare autosomal dominant disorder characterized by symmetrical swelling of the mandible and the maxilla. In patients with cherubism, the bone is replaced by a fibrous granuloma containing multinucleated giant cells, which are differentiated into activated osteoclasts<p class="abst...

hrp0084p1-120 | Puberty | ESPE2015

A Novel LHX4 Mutation is Associated with Hypogonadotropic Hypogonadism, Not Combined Pituitary Hormone Deficiency

Takagi Masaki , Daitsu Takashi , Numakura Chikahiko , Sato Takeshi , Narumi Satoshi , Hasegawa Tomonobu

Background: Mutations in HESX1, SOX3 responsible for combined pituitary hormone deficiency (CPHD) have been identified in a small number of hypogonadotropic hypogonadism (HH), suggesting that the genetic overlap between CPHD and HH.Case presentation: A 2-month-old boy was referred because of micropenis (stretched penile length 1.0 cm) with intrascrotal testes (1 ml). Hormone assays revealed very-low plasma testosterone levels (0.06 ng/m...

hrp0084p2-405 | GH &amp; IGF | ESPE2015

SGA Short Stature Bearing with a Novel Nonsense Mutation (p.W1249X) in the IGF1R Gene

Fujimoto Masanobu , Kawashima Yuki , Hamajima Takashi , Miyahara Naoki , Nishimura Rei , Hanaki Keiichi , Kanzaki Susumu

Background: The type I IGF1R plays a role in intrauterine and postnatal growth. Heterozygous IGF1R mutations have been identified in over 20 families. Some of them are linked to the etiology of short stature in previous studies. In addition, we previously reported that a heterozygous nonsense mutation (p.Q1250X) of the IGF1R gene led to decrease IGF1R protein expression through endoplasmic reticulum-associated protein degradation (ERAD) mechanism, resulted in...